Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accounts Payables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Accounts Payables for 3 consecutive years, with $355000.0 as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 68.33% to $355000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $355000.0 through Dec 2025, down 68.33% year-over-year, with the annual reading at $355000.0 for FY2025, 68.33% down from the prior year.
  • Accounts Payables for Q4 2025 was $355000.0 at Artiva Biotherapeutics, down from $848000.0 in the prior quarter.
  • The five-year high for Accounts Payables was $2.0 million in Q1 2025, with the low at $355000.0 in Q4 2025.
  • Average Accounts Payables over 3 years is $1.0 million, with a median of $984500.0 recorded in 2024.
  • The sharpest move saw Accounts Payables surged 82.57% in 2024, then plummeted 68.33% in 2025.
  • Over 3 years, Accounts Payables stood at $614000.0 in 2023, then surged by 82.57% to $1.1 million in 2024, then tumbled by 68.33% to $355000.0 in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $355000.0, $848000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.